Clinical Trial Update: A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial comparing atezolizumab to docetaxel in non-small cell lung cancer after platinum-based chemotherapy failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED